Endosomolytic peptides enable the cellular delivery of peptide nucleic acids (2024)
Sequence: RRRRRRRRRR
| Experiment Id | EXP002487 |
|---|---|
| Paper | Endosomolytic peptides enable the cellular delivery of peptide nucleic acids |
| Peptide | azide-R10 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | no |
| Peptide Concentration | 5–40 µM |
| Rna Concentration | 1–30 µM |
| Mixing Ratio | Near-stoichiometric peptide:PNA |
| Formulation Format | Peptide/PNA co-treatment or conjugate |
| Formulation Components | azide-R10 + PNA654 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa654 reporter cells |
| Animal Model | |
| Administration Route | |
| Output Type | Corrective splicing (GFP expression) |
| Output Value | Robust GFP for L17E/L17ER4 variants; minimal for R10 variants |
| Output Units | |
| Output Notes | Azide modifications preserve endosomolytic activity; R10 variants remain endosomally trapped |
| Toxicity Notes | L17ER4 variants cytotoxic at high dose |
| Curation Notes |